Treatment
Pembrolizumab clinical trials
We’re tracking 603 recruiting studies that include Pembrolizumab, each written for real people, not researchers, below.
Recruiting studies
- NCT05741164RecruitingPhase 2
Propranolol plus pembrolizumab for hard-to-treat breast cancer
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
Atlanta, GeorgiaAges 18 years+ - NCT05726370RecruitingPhase 2
Pembrolizumab plus chemo before surgery for recurrent head and neck cancer
This Phase 2 trial tests whether giving pembrolizumab (an immune therapy) plus chemotherapy before curative surgery can improve outcomes for people with resectable, recurrent head and neck squamous cell cancer. It also studies how these treatments affect the tumor and immune response using required tissue and blood samples.
Boston, MassachusettsAges 18 years+ - NCT03760575RecruitingPhase 1
Pembrolizumab plus chemo with surgery for pleural mesothelioma
This trial studies how well pembrolizumab (an immune therapy) works when added to chemotherapy before image-guided surgery for malignant pleural mesothelioma. It aims to shrink or control the cancer and improve surgical results by combining treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05651594RecruitingPhase 2
Propranolol with pembrolizumab and chemotherapy for esophageal cancer
This trial tests whether adding propranolol (a common blood-pressure/heart medicine) can improve outcomes when used with pembrolizumab plus standard chemotherapy. It is for people with advanced esophageal or gastroesophageal junction adenocarcinoma that cannot be removed with surgery.
Buffalo, New YorkAges 18 years+ - NCT05669846RecruitingPhase 2
FMT plus pembrolizumab for advanced lung cancer after prior treatment
This Phase 2 trial studies whether adding fecal microbiome transplant (FMT) to pembrolizumab can help people with advanced, PD-L1–positive non-small cell lung cancer that has returned or progressed after anti–PD-1/PD-L1 therapy. You may be asked to give new tumor tissue and undergo gut procedures, because the study aims to change gut bacteria to boost the immune response.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05633654RecruitingPhase 3
Test drug combo versus standard care for triple-negative breast cancer
This trial tests a cancer antibody-drug combination plus pembrolizumab (immunotherapy) versus standard treatment. It’s for people with triple-negative breast cancer that still has invasive disease in the breast or lymph nodes after surgery and chemotherapy before surgery.
Birmingham, AlabamaAges 18 years+ - NCT05603910RecruitingPhase 1
Drug and radiation combo for recurrent pelvic endometrial cancer
This study tests a combination of two drugs (lenvatinib and pembrolizumab) plus focused radiation to the pelvis for a specific type of endometrial cancer that has returned or cannot be surgically removed. The goal is to see if this treatment is safe and effective for tumors that are pMMR and limited to the pelvic area.
Miami, FloridaAges 18 years+ - NCT05613413RecruitingPhase 2
Maintenance cabozantinib plus pembrolizumab after lung cancer control
This trial tests whether continuing treatment with cabozantinib plus pembrolizumab after your metastatic squamous lung cancer responds (or is stable) can help people live longer and stay in control. It may be an option if your cancer has already shown it can respond to initial (first-line) treatment.
Chicago, IllinoisAges 18 years+ - NCT05570825RecruitingPhase 2
Study drug SX-682 with pembrolizumab for advanced lung cancer
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
Seattle, WashingtonAges 18 years+ - NCT05589818RecruitingPhase 2
Pembrolizumab for advanced lung cancer without key gene targets
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
New York, New YorkAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT05493566RecruitingEarly Phase 1
Low-dose IL-2 plus pembrolizumab for stage IV lung cancer
This early-phase study tests whether low-dose IL-2 combined with pembrolizumab can help treat stage IV non-small cell lung cancer that has not had prior advanced treatment. It may be an option if your tumor has certain immune-marker findings (PD-L1) and you meet safety requirements.
Atlanta, GeorgiaAges 18 years+ - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Boston, MassachusettsAges 18 years+ - NCT05420948RecruitingPhase 2
Pembrolizumab with chemotherapy for returning or spread head cancer
This Phase 2 study tests pembrolizumab (an immunotherapy) plus chemotherapy to treat head and neck cancer that has come back or spread. You might be eligible if standard local treatments won’t be curative and your tumor can be measured on scans.
Chicago, IllinoisAges 18 years+ - NCT05405595RecruitingPhase 1/Phase 2
Study drug with pembrolizumab for advanced solid tumors
This early-stage trial tests a new investigational drug (ADG126) combined with pembrolizumab in people with advanced or metastatic solid tumors. It aims to find a safe dose and see whether the combination can shrink tumors.
Scottsdale, ArizonaAges 18 years+ - NCT05319730RecruitingPhase 1/Phase 2
Testing new drugs, with or without pembrolizumab, for advanced esophageal cancer
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
Tucson, ArizonaAges 18 years+ - NCT05356741RecruitingPhase 1/Phase 2
Study drug VIR-5818 with and without pembrolizumab
This early trial tests whether VIR-5818 given through a vein is safe and whether it works better when combined with pembrolizumab. It’s for adults with HER2-positive cancers that are locally advanced or spread, and the study checks safety, side effects, and early signs of effect.
Duarte, CaliforniaAges 18 years+ - NCT05313243RecruitingPhase 2
Pembrolizumab plus brentuximab for relapsed T-cell lymphoma
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
New Haven, ConnecticutAges 18 years+ - NCT05318469RecruitingPhase 1/Phase 2
Ivermectin with immunotherapy for metastatic triple-negative breast cancer
This trial studies whether ivermectin, given together with immunotherapy (balstilimab or pembrolizumab), can help treat metastatic triple-negative breast cancer. It mainly looks at safety first, and may also explore how well the treatment works for people whose cancer has spread.
Los Angeles, CaliforniaAges 18 years+ - NCT05355051RecruitingPhase 2
Azacitidine plus pembrolizumab for Hodgkin lymphoma after relapse
This Phase 2 study tests azacitidine together with pembrolizumab in people whose Hodgkin lymphoma has come back or did not respond (relapsed/refractory). It aims to see whether this combination can control cancer and improve outcomes, especially when standard high-dose chemotherapy is not an option.
Houston, TexasAges 1 year+ - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Buffalo, New YorkAges 18 years+ - NCT05180097RecruitingPhase 2
Immunotherapy with stem cell transplant for relapsed Hodgkin lymphoma
This Phase 2 trial tests whether pembrolizumab plus brentuximab works better than standard chemotherapy followed by an autologous stem cell transplant for people whose classic Hodgkin lymphoma has come back or did not respond. It may help by improving cancer control before and around stem cell transplant and by comparing outcomes between the two treatment approaches.
Concord, New South WalesAges 18 years+ - NCT05188508RecruitingPhase 2
Pembrolizumab, olaparib, and temozolomide for recurrent glioma
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
Hartford, ConnecticutAges 18 years+
Common questions
- Are there clinical trials studying Pembrolizumab?
- Yes. Clin2 currently lists 603 recruiting studies that include Pembrolizumab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Pembrolizumab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Pembrolizumab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Pembrolizumab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.